Tests a combination of venetoclax and chemotherapy in acute myeloid leukemia
Tests venetoclax with chemotherapy in adults with acute myeloid leukemia linked to KMT2A gene changes.
Key facts
- Who runs it
- Huai'an First People's Hospital
- Where
- Huai'an, ChinaSee the site
- Trial code
- Registry title
- Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
- Status
- Recruiting
- People taking part
- 34 people, planned
- Started
- 24 May 2022
- Expected to end
- 30 Dec 2027
- Type of study
- Interventional
- Treatments tested
- Venetoclax 100 mg d1,200 mg d2,400 mg d3-14;
- Record updated
- 25 March 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 60 with newly diagnosed or relapsed/refractory acute myeloid leukemia with KMT2A (MLL) gene abnormalities. It tests the VHEA drug combination.
- Age
- 18 to 60 years
- Sex
- All sexes
- Disease stage
- Acute myeloid leukemia, newly diagnosed or relapsed/refractory
- Biomarker or test result
- KMT2A (MLL) gene abnormality
Main reasons for not taking part
- Other cancers
- Heart stent or heart intervention within 12 months, heart attack, unstable angina, or other significant heart disease
- Uncontrolled active infection or bleeding in the organs
- Pregnant or breastfeeding women
- Took part in another clinical study within 3 months
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age between 18 and 60 years old;Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Expected survival time of at least 3 months
- Does not meet any of the following criteria for severe heart, lung, liver, or kidney disease:A) History of congestive heart failure requiring treatment, or ejection fraction ≤ 50%, or presence of chronic stable angina;B) Lung diffusing capacity for carbon monoxide (DLCO) ≤ 65%, or forced expiratory volume in one second (FEV1) ≤ 65%;C) Moderate liver dysfunction, total bilirubin > 1.5 to ≤ 3.0 × upper limit of normal (ULN);D) Creatinine clearance ≥ 30 mL/min to < 45 mL/min
- No other significant contraindications to chemotherapy as determined by the physician
- Capable of understanding and willing to sign the informed consent form for this study
Who cannot take part
- Underwent cardiac vascular intervention or stent placement within 12 months prior to signing the informed consent, or history of myocardial infarction, unstable angina, or other clinically significant cardiac disease
- Participation in any other clinical study within 3 months prior to signing the informed consent
- Presence of other malignancies
- Uncontrolled active infection (including bacterial, fungal, or viral infection) and visceral bleeding
- Any other condition deemed unsuitable for participation in this study by the investigator
- Pregnant or lactating women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Where in China
- The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University#Huai'an First People's Hospital#Huai'an, ChinaContact: Shandong TaoTaking people
About the trial
What the trial wants to find out
This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA(Venetoclax with Homoharringtonine,Etoposide,Cytarabine)regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities.
Read full original descriptionShow less
This study includes the induction and consolidation phases of AML treatment.
The group in the trial
- VHEA regimen in the treatment of ND-AML and RR-AML with MLL gene abnormalities.Treatment being tested
Venetoclax 100 mg d1,200 mg d2,400 mg d3-14; homoharringtoine, HHT 2 mg/m2,qd,d1-7; Etoposide 0.1 g,qd,d1-5; Cytarabine 100 mg/m2,qd,d1-7 The patient meets the criteria for autologous hematopoietic stem cell transplantation (ASCT) during the treatment process, they can undergo ASCT.If the patient meets the criteria for transplantation and there is a suitable donor, they can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Treatment: Venetoclax 100 mg d1,200 mg d2,400 mg d3-14;
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Study Protocol for the Treatment of Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia With KMT2A Gene Abnormalities Using VHEA(Venetoclax With Homoharringtonine,Etoposide,Cytarabine)
- Plain-language title
- Tests a combination of venetoclax and chemotherapy in acute myeloid leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06328179, who can take part
- Record updated
- 25 March 2024